MedTrace Logo

Ontogeny of Measles Immunity in Infants

NCT00240916 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 750

Last updated 2022-06-09

No results posted yet for this study

Summary

This is an immunogenicity study evaluating the development of the immune response of healthy infants following primary vaccination with Attenuvax at 6 or 9 months of age compared with responses in 12 month-old infants receiving MMR-II. Responses of infants receiving an early two dose measles vaccine regimen with the first dose given at 6 or 9 months followed by a second dose administered at 12 months will also be compared to infants given a single dose at 12 months of age (Table 2). The current approved regimen for measles vaccination is a first vaccination at 12-15 months and a subsequent vaccination at school entry.

A secondary endpoint of this study will be to assess the safety of measles vaccine administered as Attenuvax at 6 or 9 months of age and in an early two dose measles vaccine regimen with Attenuvax administered at 6 or 9 months followed by MMR-II at 12 months of age.

Conditions

Interventions

BIOLOGICAL

Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)

BIOLOGICAL

MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)

Sponsors & Collaborators

Principal Investigators

  • Hayley Altman Gans · Stanford University

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1993-07-31
Primary Completion
2011-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00240916 on ClinicalTrials.gov